IVERIC bio, Inc.
DelistedCIK 1410939fmd_1MR9SG42SFCQHE5DX6MD8RZ5JMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 05, 2007 to Mar 31, 2023, 51 periods
Latest annual · FY2019
Millions- Total revenues
- 0
- Operating income
- (190)
- Net income
- (185)
- Free cash flow
- (165)
Latest quarter · Q1 FY2023
Millions- Operating income
- (74)
- Net income
- (72)
- Free cash flow
- (51)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2017 to FY2022
- n/m
IVERIC bio, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$189.9 million | -$114.8 million | 10-K 2023-03-01 · proof | |
| Net income | -$185.2 million | -$114.5 million | 10-K 2023-03-01 · proof | |
| Cash from operating activities | -$163.8 million | -$98.6 million | 10-K 2023-03-01 · proof | |
| Free cash flow | -$164.5 million | -$98.9 million | 10-K 2023-03-01 · proof | |
| Total assets | $666.8 million | $389.4 million | +71.3% | 10-K 2023-03-01 · proof |
| Total liabilities | $132.2 million | $28.8 million | +358.4% | 10-K 2023-03-01 · proof |
| Cash and cash equivalents | $476.3 million | $261.4 million | +82.2% | 10-K 2023-03-01 · proof |
- What was IVERIC bio, Inc.'s operating income in fiscal 2022?
- IVERIC bio, Inc. reported operating income of -$189.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$114.8 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What was IVERIC bio, Inc.'s net income in fiscal 2022?
- IVERIC bio, Inc. reported net income of -$185.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$114.5 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What was IVERIC bio, Inc.'s cash from operating activities in fiscal 2022?
- IVERIC bio, Inc. reported cash from operating activities of -$163.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$98.6 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What was IVERIC bio, Inc.'s free cash flow in fiscal 2022?
- IVERIC bio, Inc. reported free cash flow of -$164.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$98.9 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What are IVERIC bio, Inc.'s total assets?
- As of Dec 31, 2022, IVERIC bio, Inc. reported total assets of $666.8 million, against $389.4 million a year earlier (+71.3%). Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What are IVERIC bio, Inc.'s total liabilities?
- As of Dec 31, 2022, IVERIC bio, Inc. reported total liabilities of $132.2 million, against $28.8 million a year earlier (+358.4%). Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What are IVERIC bio, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, IVERIC bio, Inc. reported cash and cash equivalents of $476.3 million, against $261.4 million a year earlier (+82.2%). Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1410939&period_type=annual&limit=5"Information only, not investment advice.